Evidence map›Paper›PMID 33987087›Full record

ArticleFrontiers in oncology2021

An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine.

Mozhi Wang, Zhiyuan Pang, Yusong Wang, Mingke Cui, Litong Yao, Shuang Li, Mengshen Wang, Yanfu Zheng, Xiangyu Sun, Haoran Dong and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mozhi WangDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Zhiyuan PangDepartment of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Yusong WangDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Mingke CuiDepartment of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Litong YaoDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Shuang LiDepartment of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Mengshen WangDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Yanfu ZhengDepartment of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Xiangyu SunDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Haoran DongDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Qiang ZhangDepartment of Breast Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Yingying XuDepartment of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor microenvironment has been increasingly proved to be crucial during the development of breast cancer. The theory about the conversion of cold and hot tumor attracted the attention to the influences of traditional therapeutic strategies on immune system. Various genetic models have been constructed, although the relation between immune system and local microenvironment still remains unclear. In this study, we tested and collected the immune index of 262 breast cancer patients before and after neoadjuvant chemotherapy. Five indexes were selected and analyzed to form the prediction model, including the ratio values between after and before neoadjuvant chemotherapy of CD4

Indexed as

breast cancerimmunityneoadjuvant chemotherapypredictionsupport vector machine

Identifiers

PMID33987087
PMCPMC8111218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.